Overview

A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia

Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This is a study designed to evaluate the efficacy and safety of lurasidone in acutely psychotic patients with chronic schizophrenia and to confirm the non-inferiority of lurasidone relative to quetiapine XR.
Phase:
Phase 3
Details
Lead Sponsor:
Bukwang Pharmaceutical
Treatments:
Lurasidone Hydrochloride
Quetiapine Fumarate